| taspoglutide vs exenatide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo add on standard treatment | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide 10mg once weekly vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide 20mg once every 2 weeks vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide 20mg once weekly vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on MET+SU therapy : 3 trials - BC21893 - ZC22565 - BC20965
| taspoglutide vs insulin glargine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on metformin: 4 trials - BC22092 - BC21713 (vs placebo) - Ratner (20mg once weekly) - Nauck 10 once weekly vs PBO
| taspoglutide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide 10mg once weekly vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled on monotherapy : 4 trials - BC22092 - BC21713 (vs placebo) - Ratner (20mg once weekly) - Nauck 10 once weekly vs PBO
| taspoglutide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide 10mg once weekly vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients inadequately controlled with insulin: 2 trials - ZC22565 - BC20965
| taspoglutide vs insulin glargine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with insufficient glycaemic control with bitherapy: 5 trials - BC21893 - BC21625 - BC20963 - ZC22565 - BC20965
| taspoglutide vs exenatide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs insulin glargine (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs pioglitazone | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| taspoglutide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
